Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Bure Equity Interim / Quarterly Report 2023

Feb 22, 2024

2899_10-k_2024-02-22_5ce6a47a-7047-49d8-a675-d3ebb0b4ddd9.pdf

Interim / Quarterly Report

Open in viewer

Opens in your device viewer

Interim period January–December 2023

  • Net asset value was SEK 257.9 per share compared to SEK 196.3 at the beginning of the year, corresponding to an increase of 31.4 per cent.
  • Bure's net asset value was SEK 19,123M compared to SEK 14,559M at the beginning of the year.
  • Total return on the Bure share was 17.0 per cent compared to the SIX Return Index which rose 19.2 per cent.
  • Group earnings after tax amounted to SEK 4,749M (-9,235). Earnings per share amounted to SEK 64.0 (-124.7).

Interim period October – December 2023

  • Net asset value was SEK 257.9 per share compared to SEK 217.6 at the beginning of the quarter, corresponding to an increase of 18.5 per cent.
  • Bure divested 3.7 million shares in Mycronic for SEK 870M, resulting in an exit gain of SEK 813M.
  • Bure purchased 7.2 million shares in Ovzon's rights issue for SEK 33M.

Events after the balance sheet date

  • Net asset value amounted to 283.2 per share on 21 February 2024, corresponding to an increase of 9.8 per cent since the beginning of the year.
  • The Board of Directors proposes that the Annual General Meeting approves an ordinary dividend of SEK 2.50 per share (2.25).

Henrik Blomquist

CEO Bure Equity AB

After a weak third quarter, 2023 ended with a sharp rise in the fourth quarter. The SIX RX increased 13.9 per cent while Bure's net asset value per share was up 18.5 percent. Overall, 2023 was a good year for Bure. Net asset value per share increased 31.4 per cent, compared to the SIX RX which rose 19.2 per cent.

Internally, 2023 was of course dominated by the merger of ACQ and Yubico. For Bure, the transaction represented the finish line for ACQ – the SPAC project launched in March 2021. It was also the start of an exciting new development journey for Yubico as a listed company. Yubico is now Bure's third largest holding.

2023 was a successful year for several of the portfolio companies. Our listed portfolio companies – Mycronic, Xvivo and Yubico – all reported record years in terms of sales and profit. The unlisted ScandiNova reported growth of 54 per cent. Despite continued challenges at Ovzon, the company successfully launched its Ovzon 3 satellite at the end beginning of the this year. Ovzon 3 is Sweden's first commercial and privately financed geostationary satellite – a genuine landmark event.

In November, Bure sold 3.7 million shares in Mycronic for SEK 870M. Bure reduced its ownership share from 26.9 to 23.1 per cent, although still remains the single largest owner of Mycronic. The sale created operational flexibility and leeway for Bure going forward.

The outlook at the beginning of 2023 was characterised by general concern and considerable caution. However, falling inflation and the flattening of interest rates helped the stock market rise almost 20 per cent, despite various dramas during the year. As we look ahead to 2024, we have grounds for a little more optimism. The performance of most of the portfolio companies continues to be positive. The economic uncertainty remains, however, and there is still great concern geo-politically. It is therefore still important to balance growth, earnings and cash flow. In conclusion, with approximately SEK 1.4 billion in investable funds, it is my hope that 2024 will also offer several interesting investment opportunities.

Bure's net asset value and holdings

2022/12/31 2023/12/31
SEK M $%$ of
capital
Net asset
value
Value
change
$(+/-)$ 1) Investment Disposal Net asset
value
% of net
asset
value
Net asset
value per
share, SEK
Cavotec 3) 35.3% 450 35 58 $-2$ 541 2.8% 7.3
Mentice 14.7% 142 37 $\equiv$ $\equiv$ 179 0.9% 2.4
L 2
п
Mycronic 4) 23.1% 5,153 2,207 $\equiv$ $-859$ 6,500 34.0% 87.7
$\overline{\mathbf{s}}$ Ovzon $5$ ) 12.7% 338 $-214$ 83 $\overline{\phantom{m}}$ 206 1.1% 2.8
T
E
Vitrolife 15.9% 4,005 183 $\equiv$ $\overline{\phantom{0}}$ 4,188 21.9% 56.5
D Xvivo Perfusion 6) 14.3% 799 647 35 $\overline{\phantom{0}}$ 1,481 7.7% 20.0
Yubico 7) 17.5% 718 668 837 2,223 11.6% 30.0
Total listed holdings 11,605 3,562 1,013 $-862$ 15,318 80.1% 206.6
$\mathbf{u}$ Allgon 8) 91.8% 753 219 6 $-1$ 977 5.1% 13.2
$\mathbf N$
L.
Atle Investment Management 9) 93.0% 256 19 70 $-1$ 344 1.8% 4.6
т Bure Growth 10) 100.0% 1,362 378 104 $-980$ 864 4.5% 11.7
$\mathbf S$
T
Mercuri International 11) 90.4% 68 $\overline{\phantom{a}}$ $\overline{2}$ 70 0.4% 0.9
E
D
Total unlisted holdings 2,438 616 183 $-982$ 2,255 11.8% 30.4
Total holdings 14,044 4,178 1,196 $-1,844$ 17,573 91.9% 237.0
$\mathbf{T}$
$\mathbb{R}$
$\mathsf E$
Cash and cash equivalents,
short-term investments and
other assets 12)
515 1,035 1,550 8.1% 20.9
$\overline{A}$
$\mathbf S$
Total treasury 515 1,035 1,550 8.1% 20.9
$\cup$
${\sf R}$
Y
Total net asset value 14,559 4,178 2,231 $-1,844$ 19,123 100.0% 257.9

1) Change in value including exit gains/losses.

2) Bure's number of shares at 31 December 2023: Cavotec 37,554,921, Mentice 3,761,659, Mycronic 22,617,163, Ovzon 14,209,525, Vitrolife 21,510,257, Xvivo Perfusion 4,493,504 and Yubico 15,041,943. Bure also has 4,200,000 warrants in Yubico.

3) Bure subscribed to 4,408,302 shares in Cavotec's rights issue for SEK 58M. Bure divested 175,000 shares for SEK 2M to the Cavotec management team. 4) Bures divested 3.7 million Mycronic shares for SEK 870M or SEK 859M post transaction costs.

5) Bure subscribed to 8,348,491 shares in Ovzon's rights issue for SEK 83M.

6) Bure subscribed to 126,000 shares in Xvivo's rights issue for SEK 35M.

7) Prior to the merger between ACQ Bure and Yubico, Bure Growth divested the holding in Yubico to Bure in an internal transaction for SEK 971M. Yubico was then merged with ACQ Bure, whereby Bure received a merger consideration consisting of 7,851,943 shares in ACQ Bure and SEK 564M. Bure acquired an additional 190,000 shares in ACQ Bure's placement and rights issue for SEK 19M. In conjunction with the merger, ACQ Bure was renamed Yubico and listed on the First North.

8) Bure's direct and indirect holding in Allgon amounts to 91.8 per cent. The holding was revalued by SEK 218M.

9) Atle made conditional shareholder contributions to Atle Investment Services and HealthInvest Partners of SEK 8M and SEK 5M, respectively. Atle paid additional purchase fees for Atle Investment Services and HealthInvest Partners of SEK 61M. The holding in Alcur Fonder was revalued by SEK 24M. The holding in Fondbolaget Fondita was revalued downwards by SEK 5M.

10) Bure Growth subscribed for 80,934 shares in ScandiNova Systems' rights issue for SEK 36M and acquired 443 shares for SEK 0.5M. The holding in ScandiNova Systems was revalued by SEK 61M. Bure Growth acquired shares in BioLamina for SEK 62M. The holding in BioLamina was revalued by SEK 353M. Bure Growth purchased shares in My Driving Academy's rights issue for SEK 5M and divested shares to the company's management. The holding in My Driving Academy was revalued downwards by SEK 14M. Bure Growth divested 73,432 shares in Yubico following the redemption of call options and divested the remaining 2,710,370 shares in Yubico to Bure Equity in an internal transaction.

11) Fair value of equity and interest-bearing receivables.

12) Cash and cash equivalents, participations in funds and short-term investments in market-listed assets, other unlisted companies, interest-bearing receivables and other net assets.

YEAR-END REPORT 2023

Change in net asset value during 2023

Listed portfolio companies

Listed portfolio companies accounted for 80.1 per cent of net asset value compared to 79.7 per cent at the end of 2022. The total value of listed portfolio companies decreased SEK 3,713M to SEK 15,318M.

Value changes

Value changes due to fluctuations in share prices and exits during the period was SEK 3,562M.

Value changes in SEK M and share price performance 2023

Mycronic 2,207 46.8%
Yubico (shares + warrants) 668 38.3%
Xvivo Perfusion 647 80.1%
Vitrolife 183 4.6%
Mentice 37 26.2%
Cavotec 35 6.7%
Ovzon -214 -74.9%
Total 3,562

Bure's comparison index, the SIX RX, rose 19.2 per cent.

Acquisitions

Bure acquired 4,408,302 shares in Cavotec's rights issue for SEK 58M.

Bure acquired 8,348,491 shares in Ovzon's rights issues for SEK 83M.

Bure acquired 126,000 shares in Xvivo's rights issue for SEK 35M.

Bure acquired the holding in Yubico in an internal transaction from Bure Growth for SEK 971M. In the merger between ACQ Bure and Yubico, Bure received a merger consideration of 7,851,942 shares in ACQ Bure and SEK 564M. Bure acquired an additional 190,000 shares in ACQ Bure's placement of shares and rights issue for SEK 19M. ACQ Bure was then renamed Yubico AB and listed on the First North. Bure's holding in Yubico amounts to 15,041,943 shares, corresponding to 17.5 per cent of the total number of shares.

Divestments

Bure divested 3,700,000 shares in Mycronic for SEK 870M or SEK 859M post transaction costs.

Bure divested 175,000 shares in Cavotec for SEK 2M to members of the Cavotec management team.

Dividends received

Bure received share dividends of SEK 110M from Mycronic and Vitrolife.

Unlisted portfolio companies

Unlisted portfolio companies accounted for 11.8 per cent of net asset value compared to 16.7 per cent at the end of 2022. The value of unlisted portfolio companies decreased SEK 183M to SEK 2,255M.

Acquisitions and value changes

Atle paid an additional purchase price for Atle Investment Services and HealthInvest Partners of SEK 61M.

Atle made conditional shareholder contributions to Atle Investment Services and HealthInvest Partners of SEK 8M and SEK 5M, respectively.

Alcur Fonder was revalued by SEK 24M. Fondbolaget Fondita was revalued downwards by SEK 5M.

Bure Growth acquired shares in BioLamina for SEK 62M. The holding in BioLamina was revalued to SEK 353M.

Bure Growth subscribed for shares in ScandiNova Systems' rights issue for SEK 36M and acquired shares for SEK 0.5M. The holding in ScandiNova Systems was revalued by SEK 61M.

Bure Growth purchased shares in My Driving Academy for SEK 5M and divested shares to company management. The holding was revalued downwards by SEK 14M.

The holding in Allgon was revalued by SEK 218M.

Divestments

Bure Growth divested 73,432 shares in Yubico due to a redemption of call options in Yubico and divested its remaining shares in Yubico to Bure Equity in an internal transaction for SEK 971M.

Dividends received

Atle Investment Management received dividends of SEK 66M from the part-owned asset management companies. Bure received dividends of SEK 18M from Allgon and SEK 7M from AMIP.

Treasury

The value of assets in Treasury increased SEK 1,035M to SEK 1,550M. Bure acquired financial assets for SEK 381M and divested financial assets for SEK 1,444M. Bure paid dividends of SEK 167M. The group received dividends of SEK 202M. Other changes amounting to SEK -63M were due to changes in working capital, value changes in short-term investments and administrative costs.

Assets in Treasury amounted to 8.1 per cent of net asset value compared to 3.5 per cent at the end of 2022.

The Bure share

The total number of Bure shares amounts to 74,357,193, of which 74,146,921 are outstanding. The Bure Annual General Meeting (AGM) of 3 May 2023 authorised the Bure Board of Directors to decide on the buyback of up to 10 per cent of the total number of ordinary shares in Bure Equity AB. Bure did not repurchase any ordinary shares in 2023, nor does it hold any own ordinary shares.

With the authorisation of the AGM of May 3, 2023, Bure conducted a rights issue and a repurchase of 105,136 class C shares. The shares were issued and repurchased in accordance with the LTIP 2023 incentive programme, which was adopted by the AGM of May 3, 2023.

21 Feb
2024
31 Dec
2023
31 Dec
2022
31 Dec
2021
Share price, SEK 292.8 285.8 246.4 438.2
Dividend per share, SEK 2.25 2.25 2.0
Total return since year-end1) 2.4% 17.0% -43.1% 50.1%
Net asset value per share, SEK 283.2 257.9 196.3 323.2
Development of NAV per share 9.8% 31.4% -39.2% 34.9%
SIX Return Index 0.5% 19.2% -22.8% 39.3%

1) Including dividends of SEK 2.25 per share for 2023 and 2022 and SEK 2.00 per share for 2021.

SEK
500
400 285.8
300 257.9
200
100
0
11 12 13 14 15 16 17 18 19 20 21 22 23
Share price Net asset value per share

Development of Bure's net asset value and share price per share

Portfolio companies Jan – Dec 2023 and 2022
Listed SEK M
2022
1,572
-48
-3.0%
Holding 35.3% 35.4%
Net sales 274 218
EBIT -1 -24
EBIT margin -0.2% -11.0%
Holding n/a
n/a
n/a
14.7%
5,706
1,235
21.6%
23.1%
290
-95
-32.8%
12.7%
3,512
711
20.2%
15.9%
598
4
0.7%
14.3%
1 844
195
10.5%
17.5%
14.7%
2023
Net sales
EBIT
EBIT margin
Net sales
EBIT
EBIT margin
Holding
Net sales
EBIT
EBIT margin
Holding
Net sales
EBIT
EBIT margin
Holding
Net sales
EBIT
EBIT margin
Holding
Net sales2)
EBIT
EBIT margin
Holding
5,119
894
17.5%
26.9%
357
-47
-13.2%
11.4%
3,234
654
20.2%
15.9%
415
6
1.5%
14.6%
1,561
215
13.8%
n/m

1) Adjusted for write-downs not affecting cash flow of SEK 4,300M in 2023. 2) Key figures refer to Yubico. ACQ Bure is not included.

Unlisted SEK M 2023 2022
Net sales 708 617
EBIT 108 96
EBIT margin 15.3% 15.5%
Holding 91.8% 92.4%
Net sales 0 0
EBIT 65 123
EBIT margin n/m n/m
Holding 93.0% 93.0%
Net sales 0 0
EBIT 395 46
EBIT margin n/m n/m
Holding 100.0% 100.0%
Net sales 314 325
EBIT -3 2
EBIT margin
-0.8%
Holding
90.4%
0.5%
90.4%

Listed portfolio companies

www.cavotec.com

Share of Bure's net asset value: 2.8%

Cavotec is a leading engineering group that designs and manufactures automated connection and electrification systems for ports and industrial applications worldwide.

Key figure1)
EUR m
Q4
2023
Q4
2022
2023 2022 2021
Net sales n/a 47 n/a 148 116
Operating expenses n/a -48 n/a -152 -117
EBIT n/a -2 n/a -5 -1
EBIT margin n/a -3.5% n/a -3.0% -0.6%
Net financial items n/a -4 n/a 4 3
Profit/loss before tax n/a -5 n/a 0 3
Income tax expense n/a -1 n/a -3 -4
Profit/loss for the period
continuing operations
n/a -7 n7a -3 -1
Profit/loss for the period
discontinued operations
n/a -1 n/a -11 -36
Profit/loss for the period n/a -8 n/a -14 -37
Net loan debt (-)/
receivable (+)
n/a -30 -7
Total assets n/a 168 175
Equity n/a 44 67
Cash flow from operating
activities
n/a 21 1
Average no. of employees n/a 640 815

1) Cavotec's interim report is published on 23 February 2024.

Facts at 31 December 2023 Largest shareholders
NAV: SEK 541M Bure Equity 35.3%
Acquisition date: 2014 Thomas von Koch 17.5%
Board member from Bure:
Patrik Tigerschiöld, chairman
Others 47.2%

The quarter in brief

  • Cavotec received a contract from one of the world's largest shipping lines for shore power connection equipment for new-build container ships. The total value of the order was EUR 6.7M.
  • The share price fell 1.0 per cent in the fourth quarter.

www.mentice.com

Share of Bure's net asset value: 0.9%

Mentice develops and sells turn-key simulation solutions targeting the fast-growing market for endovascular procedures.

Key figure
SEK m
Q4
2023
Q4
2022
2023 2022 2021
Net sales 70 69 274 218 185
Operating expenses -74 -62 -274 -242 -205
EBIT -4 7 -1 -24 -20
EBIT margin -5.1% 9.6% -0.2% -11.0% -10.7%
Net financial items 1 0 1 0 -2
Profit/loss before tax -2 7 0 -24 -21
Income tax expense 0 -5 -3 -7 -8
Profit/loss for the period -3 2 -3 -31 -29
Net loan debt (-)/
receivable (+)
50 31 -2
Total assets 323 333 262
Equity 159 163 137
Cash flow from operating
activities
37 15 -5
Average no. of employees 122 122 104

|--|

NAV: SEK 179M Karin Howell-Bidermann 34.0%
Acquisition date: 2019 Bure Equity 14.7%
Board member from Bure: Fjärde AP-fonden 6.9%
Gösta Johannesson, Others 44.4%
board member
  • Order intake was SEK 104M (90), corresponding to an increase of 15 per cent. Orderbook at the end of the period was SEK 156M (126).
  • Net sales was SEK 70M (69), an increase of 3 per cent.
  • Operating profit was SEK -4M (7).
  • Mentice acquired important assets from Biomodex, the company's foremost competitor within flow simulation.
  • The share price rose 45.9 per cent in the fourth quarter.

www.mycronic.com

Share of Bure's net asset value: 34.0%

Mycronic creates world-leading production equipment for electronics and display manufacturing.

Key figure
SEK m
Q4
2023
Q4
2022
2023 2022 2021
Net sales 1,968 1,497 5,706 5,119 4,635
Operating expenses -1,348 -1,235 -4,471 -4,225 -3,586
EBIT 620 262 1,235 894 1,049
EBIT margin 31.5% 17.5% 21.6% 17.5% 22.6%
Net financial items 15 1 27 -4 -2
Profit/loss before tax 635 263 1,262 890 1,046
Income tax expense -125 -16 -266 -154 -219
Profit/loss for the period 510 247 996 737 827
Net loan debt (-)/
receivable (+)
1,912 1,004 440
Total assets 8,340 7,340 6,136
Equity 5,282 4,703 3,997
Cash flow from operating
activities
1,608 853 998
Average no. of employees 2,027 2,002 1,683
Facts at 31 December 2023 Largest shareholders
NAV: SEK 6,500M Bure Equity 23.1%
Acquisition date: 2010 via SEB Fonder 9.9%
Skanditek Fjärde AP-fonden 8.1%
Board member from Bure:
Patrik Tigerschiöld, chairman
Others 58.9%

The quarter in brief

  • Order intake was SEK 1,448M (2 529), a reduction of 43 per cent. Total order book at the end of the period was SEK 4,149M (3,574).
  • Net sales increased 31 per cent to SEK 1,968M (1,497).
  • Operating profit amounted to SEK 620M (262), corresponding to an operating margin of 31.5 per cent (17.5).
  • Bure divested 3.7 million shares in Mycronic for SEK 870M, resulting in an exit gain of SEK 813M.
  • The share price rose 27.2 per cent in the fourth quarter.
  • The Board of Directors has proposed the 2024 AGM approve a dividend of SEK 4.50 (3.50) per share.

www.ovzon.com

Share of Bure's net asset value: 1.1%

Ovzon offers a revolutionary mobile broadband service via satellite that combines high data speeds with high degrees of mobility.

Key figure
SEK m
Q4
2023
Q4
2022
2023 2022 2021
Net sales 91 101 290 357 191
Operating expenses -105 -110 -385 -438 -305
EBIT -14 -9 -95 -81 -113
EBIT margin -15.4% -8.6% -32.8% -22.7% -59.2%
Net financial items 27 0 28 45 29
Profit/loss before tax 12 -9 -67 -36 -84
Income tax expense 0 0 7 0 0
Profit/loss for the period 12 -9 -60 -36 -84
Net loan debt (-)/
receivable (+)
-410 -202 82
Total assets 2,190 1,922 1,853
Equity 1,780 1,393 1,450
Cash flow from operating
activities
-14 -112 -77
Average no. of employees 45 43 36
Facts at 31 December 2023 Largest shareholders
NAV: SEK 206M Bure Equity 12.7%
Acquisition date: 2018 Investment AB Öresund 12.1%
Board member from Bure: Grignolino AB 11.3%
Patrik Tigerschiöld, Others 63.9%
board member
  • Ovzon conducted a rights issue of SEK 250M in December 2023. Bure purchased 7.2 million shares in Ovzon's rights issue for SEK 33M.
  • The share price fell 35.4 per cent in the fourth quarter.
  • Ovzon's Ovzon 3 satellite was launched from SpaceX Cape Canaveral in Florida on January 4, 2024. Ovzon 3 is expected to reach its orbit in the summer of 2024.

www.vitrolife.com

Share of Bure's net asset value: 21.9%

Vitrolife Group is an international medtech group that develops, produces, and markets fertility treatment products.

Q4
2023
Q4
2022
2023 2022 2021
904 855 3,512 3,234 1,681
-719 -2,580 -1,245
185 168 711 654 435
20.5% 20.2% 25.9%
-15 -63 -123 -117 25
170 106 588 537 460
-49 -32 -139 -143 -116
121 73 449 394 344
-1,228 -1,563 -1,852
757 636 384
1,084 1,117 478
-687 -2,801
19.6% 20.2%
16,329 20,551 19,429
12,723 16,740 15,341

1) Adjusted for write-downs not affecting cash flow of SEK 4,300M in the fourth quarter 2023.

Facts at 31 December 2023 Largest shareholders
NAV: SEK 4,188M William Demant Invest A/S 28.7%
Acquisition date: 2010 Bure Equity 15.9%
via Skanditek AMF Pension & Fonder 5.1%
Board member from Bure:
Henrik Blomquist, board member
Others 50.3%

The quarter in brief

  • Net sales increased 6 per cent to SEK 904M (855). Growth in local currencies was 5 per cent.
  • Operating profit before depreciation (EBITDA) amounted to SEK 294M (273), corresponding to a margin of 32.5 per cent (31.9).
  • Adjusted EBIT was SEK 185M (168). During the period, a non-cash affecting write-down of SEK 4,300M was reported under other operating expenses.
  • The share price rose 32.4 per cent in the fourth quarter.

www.xvivoperfusion.com

Share of Bure's net asset value: 7.7%

Xvivo Perfusion is an international medtech company that develops solutions for organ, tissue and cells during transplantation procedures.

Q4
2023
Q4
2022
2023 2022 2021
156 132 598 415 258
-172 -129 -593 -409 -277
-16 2 4 6 -18
-10.4% 1.8% 0.7% 1.5% -7.2%
82 0 90 16 25
66 3 95 22 7
3 -2 -3 -4 1
68 1 92 18 8
515 237 393
2,181 1,733 1,543
1,945 1,430 1,285
46 28 -12
150 133 113
Facts at 31 December 2023 Largest shareholders
NAV: SEK 1,481M Bure Equity 14.3%
Acquisition date: Lex Asea Fjärde AP-fonden 9.0%
distribution from Vitrolife Swedbank Robur Fonder 7.8%
in 2012 Others 68.9%
Board member from Bure:
Gösta Johannesson, chairman
  • Net sales amounted to SEK 156M, corresponding to an increase of 18 per cent in SEK and 16 per cent in local currencies. Organic growth amounted to 12 per cent and acquired growth was 4 per cent.
  • Operating profit before depreciation (EBITDA) amounted to SEK 21M (14), corresponding to a margin of 13 per cent (10).
  • Operating profit (EBIT) was SEK -16M and was affected by write-downs of the PrimECC project of SEK16M.
  • The American heart preservation study conducted its first transplant during the quarter.
  • The share price rose 20.0 per cent in the fourth quarter.

Share of Bure's net asset value: 11.6%

Yubico is a global cybersecurity company that developed the YubiKey hardware, a security key that prevents account takeovers. Since the company was founded in 2007, it has been a leader in setting global standards for secure access to computers, mobile devices, servers, browsers and internet accounts.

Q4
2023
Q4
2022
2023 2022 2021
560 469 1,844 1,561 867
-465 -401 -1,650 -1,346 -934
95 68 195 215 -67
17.0% 14.4% 10.5% 13.8% -7.7%
0 1 3 5 11
96 68 198 220 -56
-17 41 -55 35 -4
78 110 142 256 -60
508 232 199
1,474 1,122 735
1,142 733 436
98 33 -53
437 377 n/a

1) Key figures refer to Yubico. ACQ Bure is not included.

Facts at 31 December 2023 Largest shareholders
NAV: SEK 2,223M1) Bure Equity 17.5%
Acquisition date: 2023 AMF Tjänstepension &
Board member from Bure: Fonder 12.1%
Patrik Tigerschiöld, chairman Stina Ehrensvärd 10.2%
Gösta Johannesson, Others 60.2%
board member

1) Refers to shares and warrants in Yubico AB.

  • Order intake increased by 83.5 percent to SEK 684M (373). Subscriptions accounted for 18.9 percent (17.2) of the bookings.
  • Net sales increased by 19.5 percent more SEK 560M (469). In local currencies, the growth was 17.8 percent. Revenue from subscriptions was responsible 14.0 (11.5) percent of net sales.
  • The gross profit amounted to SEK 466M (388), corresponding to a gross margin of 83.2 percent (82.8).
  • Operating profit was SEK 95M (68), corresponding to a margin of 17.0 percent (14.4).
  • The share price rose of 11.0 per cent in the fourth quarter.

Unlisted portfolio companies

www.allgon.se

Share of Bure's net asset value: 5.1%

Allgon is a world-leading actor in industrial radio remote controls. The company develops, manufactures, and delivers industrial radio remote control solutions for customers worldwide.

Key figure
SEK m
Q4
2023
Q4
2022
2023 2022 2021
Net sales 178 159 708 617 527
Operating expenses -158 -129 -600 -521 -467
EBIT 20 29 108 96 60
EBIT margin 11.1% 18.5% 15.3% 15.5% 11.4%
Net financial items -4 -1 -15 -6 -21
Profit/loss before tax 16 28 93 89 39
Income tax expense -8 -7 -19 -17 -4
Profit/loss from
remaining operations
8 21 74 73 35
Profit/loss from
discontinued operations
40
Profit/loss for the period 8 21 74 73 75
Net loan debt (-)/
receivable (+)
-103 -172 -210
Total assets 872 830 737
Equity 500 460 365
Cash flow from operating
activities
115 60 40
Average no. of employees 408 377 360
Facts at 31 December 2023 Largest shareholders
NAV: SEK 977M Bure Equity 91.8%
Acquisition date: 2021 Management and board
Board member from Bure:
Sophie Hagströmer, chairman
Oskar Hörnell, board member
of Allgon 8.2%

The quarter in brief

  • Net sales increased 12 per cent to SEK 178M (159).
  • Operating profit was SEK 20M (29) corresponding to a margin of 11.1 per cent (18.5).
  • Net debt was SEK 103M (172).

www.atle.se

Share of Bure's net asset value: 1.8%

Atle Investment Management invests in financial services and assets. The company owns 30.4% of Alcur Fonder, 100% of Atle Fund Services, 100% of Atle Investment Services, 20.1% of Fondbolaget Fondita, 66.7% of HealthInvest Partners, 100% of Humle Fonder, 35.2% of Teknik Innovation Norden Fonder (TIN Fonder) and holdings in equity funds.

Key figure
SEK m
Q4
2023
Q4
2022
2023 2022 2021
Net sales 0 0 0 0 0
Dividends 0 0 66 120 98
Fair value of financial
assets
11 -4 11 11 58
Management costs -5 -2 -12 -8 -5
EBIT 7 -7 65 123 151
Net financial items -2 -1 -7 -3 -1
Profit/loss before tax 5 -8 58 120 150
Income tax expense 0 0 0 0 0
Profit/loss for the period 5 -8 58 120 150
Net loan debt (-)/
receivable (+) 1)
-141 -73 -12
Total assets 389 284 229
Equity 204 191 187
Cash flow from operating
activities
55 109 95
Average no. of employees 2 1 1

1) Of which, SEK 147M is liable to Bure Equity as at 31 December 2023.

Facts at 31 December 2023 Largest shareholders
NAV: SEK 344M Bure Equity 93.0%
Acquisition date: Established 2014 Gustav Ohlsson 7.0%
Board member from Bure:
Henrik Blomquist, chairman
Oskar Hörnell, board member
  • Capital under management in Alcur Fonder, Fondita, HealthInvest Partners, Humle Fonder and TIN Fonder amounted to SEK 33 billion (34).
  • Alcur Fonder was revalued by SEK 24M. Fondbolaget Fondita was revalued downwards by SEK 5M.
  • Atle made a conditional shareholder contribution to HealthInvest Partners of SEK 5M.

www.bure.se

Share of Bure's net asset value: 4.5%

Bure Growth is a wholly owned company that invests in development companies. The company owns 51.7% in BioLamina, 31.7% in My Driving Academy Sweden, 28.1% in ScandiNova Systems.

Key figure
SEK m
Q4
2023
Q4
2022
2023 2022 2021
Net sales 0 0 0 0 0
Fair value of financial
assets
-16 0 395 46 32
Administrative expense 0 0 0 0 0
EBIT -16 0 395 46 32
Net financial items 0 0 0 0 0
Profit/loss before tax -16 0 395 46 32
Income tax expense 0 0 0 0 0
Profit/loss for the period -16 0 395 46 32
Net loan debt (-)/
receivable (+) 1)
425 -449 -435
Total assets 1,297 1,362 1,303
Equity 1,289 894 848
Cash flow from operating
activities
0 0 0
Average no. of employees 0 0 0

1) Of which, SEK 425M is a claim on Bure Equity as at 31 December 2023.

Facts at 31 December 2023 Largest shareholders
NAV: SEK 864M
Acquisition date: Established 2015
Bure Equity 100.0%
Board member from Bure:
Henrik Blomquist, chairman
Sophie Hagströmer, board member
Max Jonson, board member

The quarter in brief

  • Bure Growth acquired shares for SEK 5M in My Driving Academy's rights issue. Bure divested 80 shares in My Driving Academy to the management team. The holding in My Driving Academy was revalued downwards by SEK 14M.
  • Bure Growth acquired shares in BioLamina for SEK 0.3M and ScandiNova Systems for SEK 0.5M.

Share of Bure's net asset value: 0.4%

Mercuri International is a leading sales and management training consultancy and is present worldwide.

Key figure
SEK m
Q4
2023
Q4
2022
2023 2022 2021
Net sales 85 101 314 325 303
Operating expenses -85 -91 -317 -323 -299
EBIT 0 9 -3 2 4
EBIT margin 0.3% 9.1% -0.8% 0.5% 1.4%
Net financial items -5 -3 -8 -1 -4
Profit/loss before tax -4 6 -11 1 0
Income tax expense -3 -5 -2 -6 -4
Profit/loss for the period -7 2 -13 -5 -4
Net loan debt (-)/
receivable (+)1)
-105 -92 -79
Total assets 320 346 320
Equity 104 118 105
Cash flow from operating
activities
-6 -8 31
Average no. of employees 181 194 202

1) Of which, SEK 35M is liable to the Bure Equity as at 31 December 2023.

Facts at 31 December 2023 Largest shareholders
NAV: SEK 70M1) Bure Equity 90.4%
Acquisition date: 1998 Others 9.6%
Board member from Bure:
Henrik Blomquist, chairman

1) Fair value of equity and interest-bearing receivables.

  • Sales decreased 15 per cent to SEK 85M (101).
  • EBIT was SEK 0M (9) and EBIT margin was 0.3 per cent (9.1).
  • Net debt was SEK 105M (92).

Year-end Report January – december 2023

Bure is an investment entity, which means that the holdings varies in line with its acquisitions and divestitures. Since this makes the Group's consolidated statements difficult to analyse, the development and financial position of the companies should also be analysed on an individual basis. More detailed information on portfolio companies are presented on pages 6–11.

Consolidation principles from 1January 2021

Bure Equity is an investment entity in accordance with IFRS 10 – Investment entity.

An investment company does not consolidate subsidiaries in accordance with IFRS 10 Consolidated Financial Statements and does not apply IFRS 3 Business Combinations, with the exception of subsidiaries that are active in investment activities. An investment entity values portfolio companies at fair value in accordance with IFRS 9 Financial Instruments.

Since 1 January 2021, the Bure Group consists of the parent company Bure Equity AB, Atle Investment Management AB, and Bure Growth AB. For more information, please see Note 1 – Accounting principles.

GROUP Results for the fourth quarter of 2023

Group earnings from investment activities amounted to SEK 2,990M (2,421).

Dividends amounted to SEK 7M (0).

Fair value changes from financial assets amounted to SEK 2,982M (2,420).

Operating profit for the period was SEK 2,963M (2,405). Net financial items amounted to SEK 11M (4).

Profit after financial items was SEK 2,974M (2,409). Profit after tax was SEK 2,974M (2,409).

Other comprehensive income included translation differences of SEK 0M (0).

Results for January – December 2023

Group earnings from investment activities amounted to SEK 4,814M (-9,166). Dividends amounted to SEK 202M (217). Fair value changes from financial assets amounted to SEK4,607M (-9,390). Operating profit for the period was SEK 4,731M (-9,246). Net financial items amounted to SEK 19M (12). Profit after financial items was SEK 4,749M (-9,235).

Profit after tax was SEK 4,749M (-9,235). Other comprehensive income included translation differences of SEK 0M (0).

Financial position

Group equity at the end of the period amounted to SEK 19,131M (14,548) and the equity to assets ratio was 100 per cent (99). At the end of the year, the group had reported net receivables of SEK 1,496M (456), which consisted of interest-bearing assets of SEK 1,499M (459) and interest-bearing liabilities of SEK 3M (3). Group equity per share amounted to SEK 257.3 compared to SEK 195.9 per share on December 31, 2022.

PARENT COMPANY Results for the fourth quarter of 2023

Earnings from investment activities was SEK2,995M (2,426). Dividends amounted to SEK 7M (0). Fair value changes from financial assets amounted to SEK 2,986M (2,424). Administrative costs amounted to SEK 23M (14). Net financial items amounted to SEK 13M (5). Profit after tax was SEK2,985M (2,417).

Results for January – December 2023

Earnings from investment activities was SEK 4,384M (-9,237). Dividends amounted to SEK 178M (202). Fair value changes from financial assets amounted to SEK 4,200M (-9,446). Administrative costs amounted to SEK 71M (72). Net financial items amounted to SEK 26M (15). Profit after tax was SEK 4,338M (-9,294).

Financial position

Equity in the Parent Company at the end of the year amounted to SEK 17,660M (13,484) and the equity to assets ratio was 97 per cent (100). At the end of the year, the Parent Company had a reported net receivables of SEK 1,627M (520), which consisted of interest-bearing assets of 1,630M (523) and interest-bearing liabilities of SEK 3M (3). Receivables from Atle Investment Management and Bure Growth amounted to SEK 147M (531).

Group acquisitions and disposals

The merger between ACQ Bure and Yubico was completed. Bure acquired the holding in Yubico in an internal transaction from Bure Growth for SEK 971M. From the merger between ACQ Bure and Yubico, Bure received a merger consideration of 7,851,942 shares in ACQ Bure and SEK 564M. Bure acquired an additional 190,000 shares in ACQ Bure's placement of shares and new issue for SEK 19M. ACQ Bure was subsequently renamed Yubico AB and listed on the First North. Bure's holding in Yubico amounts to 15,041,943 shares, corresponding to 17.5 per cent of the total number of shares.

Bure acquired 4,408,302 shares in Cavotec's rights issue for SEK 58M.

Bure acquired 8,348,491 shares in Ovzon's rights issues for SEK 83M.

Bure acquired 126,000 shares in Xvivo's rights issue for SEK 35M.

Atle paid an additional purchase price for Atle Investment Services and HealthInvest Partners of SEK 61M.

Atle made conditional shareholder contributions to Atle Investment Services and HealthInvest Partners of SEK 8M and SEK 5M, respectively.

Bure Growth subscribed to shares for SEK 36M in ScandiNova Systems' rights issue. The holding was revalued by SEK 61M.

Bure Growth acquired shares in BioLamina for SEK 62M. The holding in BioLamina was revalued by SEK 353M.

Bure Growth subscribed to shares in My Driving Academy for SEK 5M. The holding was written down by SEK 14M.

Bure issued 150,000 stock options and divested 175,000 shares in Cavotec to members of the Cavotec management team for SEK 1M respectibely SEK 2M.

Bure sold 3.7 million shares in Mycronic for SEK 870M, which resulted in an exit gain of SEK 813M.

Group loss carryforward

Group loss carryforward at the end of 31 December 2023 amounted to SEK 759M, of which SEK 736M pertained to the Parent Company. Losses attributable to Sweden amounted to SEK 759M and are perpetual. The deferred tax asset based on loss carryforwards in the Group has been valued at SEK 0M (0).

Currency exposure

The majority of consolidated revenue is denominated in SEK and EUR. Underlying costs are generally incurred in the same currency as revenues, thereby limiting transaction exposure.

Related party transactions

ACQ Bure AB (publ.) was a Swedish acquisition company listed on the Nasdaq Stockholm. Bure's ownership stake holding in ACQ Bure amounted to 20 per cent. Between December 21, 2020 and September 20, 2023, Henrik Blomquist, (Bure Equity CEO), was also CEO on a consulting basis in ACQ Bure, Max Jonson, (Bure Equity CFO), was CFO on a consulting basis in ACQ Bure and Oskar Hörnell, (Investment Manager in Bure Equity), was active on a consulting basis in ACQ Bure. Bure Equity further assisted ACQ Bure with investment advisory services. These contracts were entered into on market terms. Bure Equity invoiced ACQ Bure from April 1, 2021 to September 20, 2023. Invoicing ended with the merger of ACQ Bure and Yubico AB on September 20, 2023. No other transactions with related parties took place during the period.

Ownership structure

Bure's largest shareholders on 31 December 2023 were Patrik Tigerschiöld including related parties with 10.4 per cent, AMF Tjänstepension & Fonder 9.9 per cent, the Björkman family including foundations with 8.2 per cent, Fjärde AP-fonden 7.8 per cent and SEB Investment Management 6.1 per cent. According to Holdings, the number of shareholders on 31 December 2023 was 53,509.

Events after the balance sheet date

The Board of Directors proposes that the AGM approves an ordinary dividend of SEK 2.50 per share (2.25).

Significant risks and uncertainties

In view of the rapid on the financial markets, special emphasis is placed on monitoring the effects of Bure's investments and their valuations. Bure has a number of basic principles regarding the management of risk. Bure's financial policy states that the Parent Company shall be essentially debt-free. Furthermore, each portfolio company shall be financially independent from the Parent Company, which means that the Parent Company is not financially liable for portfolio companies' obligations, and that portfolio companies are responsible for their own financing.

Financing of respective portfolio companies shall be appropriate to each company's specific circumstances, such that overall risk is managed through a balance between operational and financial risk.

Bure's 2022 annual report provides a detailed description of the Group's risk exposure and risk management in the administration report and in Note 15. Bure's assessment is that no significant risks have arisen other than those described in the annual report and in this interim report. This interim report has not been subject to review by the auditors.

Stockholm 22 February 2024

Bure Equity AB (publ)

Patrik Tigerschiöld (Chairman)

Carl Björkman Carsten Browall

Charlotta Falvin Sarah McPhee Birgitta Stymne Göransson

Henrik Blomquist (CEO)

Statement of comprehensive income

SEK M Q4
2023
Q4
2022
Full year
2023
Full year
2022
Operating income
Net sales 0 0 0 0
Dividends 7 202 217
Change fair value financial assets 2,982 2,420 4,607 -9,390
Other operating income 1 2 6 7
Total operating income 2,990 2,421 4,814 -9,166
Operating expenses
Other external expenses -10 -6 -31 -26
Personnel costs -16 -9 -48 -49
Amortization and write-downs of intangible and tangible fixed assets -1 -1 -5 -4
Total operating expenses -27 -16 -84 -80
Operating profit/loss 2,963 2,405 4,731 -9,246
Interest income and similar profit/loss items 11 4 19 12
Interest expenses and similar profit/loss items 0 0 0 0
Profit/loss after financial items 2,974 2,409 4,749 -9,235
Tax on income for the period 0 0 0 0
Income for the period 2,974 2,409 4,749 -9,235
Other comprehensive income
Items that can be subsequently re-entered onto the income statement
Translation differences 0 0 0 0
Other comprehensive income for the period, after tax 0 0 0 0
Total income for the period 2,974 2,409 4,749 -9,235
Profit/loss attributable to non-controlling interests 0 -1 4 8
Profit/loss attributable to owners of the Parent Company 2,973 2,410 4,745 -9,243
Comprehensive income attributable to non-controlling interests 0 -1 4 8
Comprehensive income attributable to owners of the Parent Company 2,973 2,410 4,745 -9,243
Average number of outstanding shares before dilution, thousands1) 74,147 74,147 74,147 74,147
Average number of outstanding shares post dilution, thousands1) 74,313 74,202 74,267 74,161
Earnings per share attributable to the parent company's shareholders
before dilution, SEK1)
40.10 32.50 64.00 -124.66
Earnings per share attributable to the parent company's shareholders
post dilution, SEK1) 40.01 32.48 63.89 -124.66

1) As of 31 December 2023, the number of possible additional ordinary shares amounts to 210,272. As of 31 December 2022, the number of possible additional ordinary shares amounts to 105,136.

Statement of financial position

SEK M 31 December
2023
31 December
2022
Assets
Intangible and tangible fixed assets 33 36
Financial assets valued at fair value via the income statement 17,529 14,027
Long-term interest-bearing receivables 45 41
Long-term non-interest-bearing receivables 1 1
Financial assets 17,575 14,069
Total fixed assets 17,608 14,105
Short-term interest-bearing receivables 1 2
Other non-interest-bearing receivables 3 4
Financial investments 122 116
Cash and cash equivalents 1,454 416
Total current assets 1,580 538
Total assets 19,188 14,643
of which, interest-bearing assets 1,499 459
Equity and liabilities
Equity attributable to owners of the Parent Company 19,117 14,535
Equity attributable to non-controlling interests 14 13
Total equity 19,131 14,548
Provisions 2 19
Non-current liabilities 16 53
Current liabilities 38 23
Total liabilities 57 95
Total equity and liabilities 19,188 14,643
of which, interest-bearing liabilities 3 3

Statement of changes in equity

SEK M Share
capital
Other
contributed
capital
Reserves Retained
earnings
incl. profit
for the period
Total Non-controlling
interests
Total
equity
Opening balance equity at 1 January 2022 576 1,660 -60 21,768 23,943 13 23,956
Profit/loss for the year -9,243 -9,243 8 -9,235
Other comprehensive income 0 0 0
Share-related remuneration LTIP 2022 1 1 1
Issue of class C shares 1 1 1
Buyback of class C shares -1 -1 -1
Dividends -167 -167 -167
Dividends paid to minority shareholders -8 -8
Closing balance equity at 31 December 2022 577 1,660 -60 12,359 14,535 13 14,548
Opening balance equity at 1 January 2023 577 1,660 -60 12,359 14,535 13 14,548
Profit/loss for the year
4,745 4,745 4 4,749
Closing balance equity at 31 December 2023 577 1,660 -60 16,940 19,117 14 19,131
Dividends paid to minority shareholders -3 -3
Cash dividend -167 -167 -167
Buyback of class C shares -1 -1 -1
Issue of class C shares 1 1 1
Share-related remuneration LTIP 2023 2 2 2
Share-related remuneration LTIP 2022 2 2 2
Other comprehensive income 0 0 0 0
Profit/loss for the year 4,745 4,745 4 4,749

Statement of cash flows

Q4 Q4 Full year Full year
SEK M 2023 2022 2023 2022
Cash flow from operating activities before changes
in working capital 805 -7 1,369 176
Cash flow from changes in working capital 28 15 -1 0
Cash flow from operating activities 833 7 1,368 176
Cash flow from investing activities -26 -77 -124 39
Cash flow from financing activities 15 51 -206 -125
Cash flow for the period 821 -19 1,038 90
Cash and cash equivalents at beginning of period 632 435 416 326
Cash flow for the period 821 -19 1,038 90
Translation differences 0 0 0 0
Cash and cash equivalents at end of period 1,454 416 1,454 416

Income statement

Q4 Q4 Full year Full year
SEK M 2023 2022 2023 2022
Investment activities
Dividends 7 178 202
Change fair value financial assets 2,986 2,424 4,200 -9,446
Other income 1 2 6 7
Total income 2,995 2,426 4,384 -9,237
Personnel costs -13 -8 -44 -46
Other external expenses -9 -5 -25 -24
Depreciation of property, plant and equipment -1 -1 -2 -2
Total management costs -23 -14 -71 -72
Operating profit/loss 2,972 2,412 4,313 -9,309
Financial income and expenses
Interest income and similar profit/loss items 13 5 26 15
Interest expenses and similar profit/loss items 0 0 0 0
Total financial income and expenses 13 5 26 15
Financial income and expenses 2,985 2,417 4,338 -9,294
Tax on income for the period 0 0 0 0
Profit/loss for the period1) 2,985 2,417 4,338 -9,294
Average number of employees 8 9 8 9

1) Corresponds to comprehensive income.

Statement of financial position

SEK M 31 December
2023
31 December
2022
Assets
Property, plant and equipment 8 8
Financial assets valued at fair value via the income statement 16,330 12,394
Shares in group companies 21 21
Long-term interest-bearing receivables 35 33
Long-term non-interest-bearing receivables 1 1
Financial assets 16,387 12,448
Total fixed assets 16,395 12,456
Short-term interest-bearing receivables 147 83
Other non-interest-bearing receivables 16 456
Short-term investments 107 98
Cash and cash equivalents 1,448 408
Total current assets 1,719 1,045
Total assets 18,114 13,501
of which, interest-bearing assets 1,630 523
Equity and liabilities
Total equity 17,660 13,484
Provisions 0 0
Non-current liabilities 1 2
Current liabilities 453 15
Total liabilities 454 17
Total equity and liabilities 18,114 13,501
of which, interest-bearing liabilities 3 3

Statement of changes in equity

Q4 Q4 Full year Full year
SEK M 2023 2022 2023 2022
Equity at beginning of period 14,673 11,066 13,484 22,944
Share-related remuneration LTIP 2022 0 1 2 1
Share-related remuneration LTIP 2023 1 2
Issue of class C shares 1 1 1 1
Buyback of class C shares -1 -1 -1 -1
Dividends -167 -167
Profit/loss for the year 2,985 2,417 4,338 -9,294
Closing balance equity 17,660 13,484 17,660 13,484

Statement of cash flows

SEK M Q4
2023
Q4
2022
Full year
2023
Full year
2022
Cash flow from operating activities before changes in working capital 813 -4 1 368 169
Cash flow from changes in working capital 11 6 3 -10
Cash flow from operating activities 824 -2 1 371 159
Cash flow from investing activities 2 -9 -594 121
Cash flow from financing activities 7 0 264 -168
Cash flow for the year 833 -7 1 040 112
Cash and cash equivalents at beginning of period 615 415 408 296
Cash flow for the year 833 -7 1 040 112
Cash and cash equivalents at end of year 1 448 408 1 448 408

Multi-year overview

Data per share) 2023 2022 2021 2020 2019
Net asset value, SEK 257.9 196.3 323.2 239.6 196.6
Share price, SEK 285.8 246.4 438.2 293.6 212.0
Share price as a percentage of net asset value 111% 125% 136% 123% 108%
Parent Company basic equity per share, SEK 237.5 181.6 309.4 226.8 183.6
Parent Company equity per share excl. buybacks, SEK 238.2 181.9 309.4 226.8 183.6
Group basic equity per share, SEK 257.3 195.9 323.1 238.7 196.8
Group equity per share excl. buybacks, SEK 258.0 196.2 323.1 238.7 196.8
Group basic earnings per share, SEK1) 64.0 -124.7 85.8 45.1 61.3
Number of shares, thousands 74,357 74,252 74,147 74,147 68,972
Number of shares excluding share buybacks, thousands 71,147 74,147 74,147 74,147 68,972
Average basic number of shares, thousands 74,267 74,161 74,147 71,757 68,972
Key figures
Dividend, SEK per share 2.25 2.25 2.0 1.0 2.0
of which, extraordinary dividend, SEK per share
Direct return 0.8% 0.9% 0.5% 0.3% 0.9%
Total return 17.0% -43.1% 50.1% 39.2% 97.9%
Market capitalisation, SEK M 21,191 18,270 32,491 21,770 14,622
Net asset value, SEK M 19,123 14,559 23,964 17,763 13,563
Return on equity 27.9% -48.0% 31.3% 22.0% 35.6%
Management expenses/Net asset value 0.37% 0.49% 0.30% 0.29% 0.33%
Parent Company results and financial position
Profit/loss after tax, SEK M 4,338 -9,294 6,237 3,242 3,850
Total assets, SEK M 18,114 13,501 22,972 16,845 12,688
Equity, SEK M 17,660 13,484 22,944 16,819 12,662
Equity/assets ratio 97% 100% 100% 100% 100%
Cash and cash equivalents and short-term investments, SEK M 1,555 506 417 1,460 800
Consolidated profit and financial position
Net sales, SEK M 0 0 0 267 382
Profit/loss after tax, SEK M 4,749 -9,235 6,362 3,236 4,229
Total assets, SEK M 19,188 14,643 24,004 17,935 13,786
Equity, SEK M 19,131 14,548 23,956 17,702 13,573
Equity/assets ratio 100% 99% 100% 99% 98%
Net loan debt (-)/receivable (+), SEK M 1,496 456 469 1,166 648
Average number of employees 10 10 9 229 226

1) As of 31 December 2023, the number of possible additional ordinary shares amounts to 210,272. As of 31 December 2022, the number of possible additional ordinary shares amounts to 105,136. There was no dilution effect during the other periods.

Notes

Note 1 – Accounting policies

Bure applies International Financial Reporting Standards (IFRS) as endorsed for application in the EU. This interim report has been prepared in compliance with IAS 34, Interim Financial Reporting, the Swedish Annual Accounts Act and the Swedish Financial Reporting Board's recommendation RFR 2, Accounting for Legal Entities.

Group consolidation principles

Bure Equity is an investment entity in accordance with IFRS 10 – Investment entity.

An investment entity does not consolidate subsidiaries in accordance with IFRS 10 Consolidated Financial Statements and does not apply IFRS 3 Operating Acquisitions with the exception of subsidiaries that are active in investing activities. An investment entity values portfolio companies at fair value in accordance with IFRS 9 Financial Instruments.

Since 1 January 2021, the Bure Group consists of the parent company Bure Equity AB, Atle Investment Management AB and Bure Growth AB.

Parent company accounting principles

The parent company's investments in companies and other financial assets are reported at fair value as profit and loss in the same way as for the group.

For further information on accounting and valuation principles, please see Note 1 in the 2022 annual report.

New accounting principles applied from 1 January 2023: revised or amended IFRS standards are not considered to have any significant impact on earnings or balance statements. Bure continuously updates its analysis of upcoming changes.

Note 2 – Segment reporting

All activities in the entity are considered to constitute a single segment.

Note 3 – Effects of changed estimates and assessments

Important estimates and assessments are presented in Note 1 in the 2022 annual report. No changes to these estimates and assessments have been that could have a significant impact on the current interim report.

Note 4 – Financial instruments

Fair value and book value of financial assets and liabilities Fair value has been calculated for all financial assets and liabilities in accordance with IFRS 13. Fair value is estimated to be equal to the book value of accounts receivable and other receivables, other current receivables, cash and other cash and cash equivalents, accounts payable, and other liabilities and borrowing. Book value less write-downs is an estimated fair value for accounts receivable and accounts payable. For long-term non-interest-bearing liabilities, fair value has been calculated by discounting future cash flows with current market interest rates regarding the term of the debt.

The investment entity's financial assets and liabilities are classified in accordance with IFRS 13 in the following three categories

  • Level 1: Listed prices in an active market for identical assets or liabilities.
  • Level 2: Other observable data for the asset or liability other than listed prices included in Level 1, either directly or indirectly.
  • Level 3: Data for the asset or liability that are not in their entirety based on observable market data.

Bure reports listed holdings at fair value with changes in value in the income statement (Level 1). Bure's listed holdings consist of Cavotec SA, Mentice AB, Mycronic AB, Ovzon AB, Vitrolife AB, Xvivo Perfusion AB, and Yubico AB.

Bure reports investments in unlisted companies (Level 3) at fair value. Unlisted companies include Allgon AB, Alcur Fonder AB, AMIP AB, Atle Fund Services AB, Atle Investment Services AB, BioLamina AB, Fondbolaget Fondita Ab, HealthInvest Partners AB, Mercuri International Group AB, My Driving Academy Sweden AB, ScandiNova Systems AB, and Technology Innovation Norden Fonder AB. In 2023, in conjunction with the merger of ACQ Bure and Yubico, the holding in Yubico has been moved from Level 3 to Level 1.

Bure has chosen to market value all financial assets based on International Private Equity and Venture Capital Valuation Guidelines (IPEV). The guidelines describe a number of methods for determining the fair value of each holding. Considerable emphasis is placed on recently completed market transactions in the company, e.g., share issues or the acquisition of existing shares. Transactions in comparable companies can also be used. Other valuation methods include discounting of forecast cash flows with relevant discount rates and applying valuation multiples such as EV/Sales, EV/EBITDA, EV/EBITA, EV/EBIT, PER and P/AuM which are adjusted to take into account differences in market, business, and risk. In general, a liquidity discount is also applied for unlisted assets. Valuation takes place on an ongoing basis and is published in conjunction with quarterly reports.

Note 4 – Financial instruments (cont.)

Real value hierarchy, Group

31 December 2023 31 December 2022
SEK M Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total
Financial assets
Financial assets at fair value from the income statement 15,065 253 2,211 17,529 11,550 55 2,422 14,027
Other long-term receivables 1 45 45 1 41 42
Financial investments 122 122 116 116
Total financial assets 15,188 253 2,256 17,697 11,667 55 2,463 14,185
Financial liabilities
Leasing liabilities 3 3 3 3
Other long-term liabilities 1 15 16 1 51 52
Accrued expenses and prepaid income 18 18 11 11
Total financial liabilities 1 36 37 1 65 66

Valuation of unlisted assets at 31 December 2023

SEK M Holding Group book value Valuation model
Holdings in Bure Equity AB
Allgon AB and AMIP AB 91.1% / 7.5% 977 EV/EBIT, PER
Mercuri International Group AB 90.4% 35 EV/EBIT, DCF
Holdings in Atle Investment Management AB 335
Alcur Fonder AB 30.4% EV/EBIT, P/AuM
Atle Fund Services AB 100.0% Accrued acquisition value/NAV of equity
Atle Investment Services AB 100.0% Accrued acquisition value /NAV of equity
Fondbolaget Fondita Ab 20.1% P/AuM, EV/EBIT
HealthInvest Partners AB 66.7% Accrued acquisition value/NAV of equity
Teknik Innovation Norden Fonder AB 35.2% EV/EBIT, P/AuM
Holdings in Bure Growth AB 864
BioLamina AB 51.7% Latest transaction
My Driving Academy Sweden AB 31.7% Latest transaction, DCF
ScandiNova Systems AB 28.1% Latest transaction
Valuation of unlisted assets at 31 December 2022
SEK M Holding Group book value Valuation model
Holdings in Bure Equity AB
Allgon AB and AMIP AB 91.1% / 14.5% 753 EV/EBIT, PER
Mercuri International Group AB 90.4% 35 EV/EBIT, DCF
Holdings in Atle Investment Management AB 272
Alcur Fonder AB 30.4% P/AuM
Atle Investment Services AB 100.0% Accrued acquisition value/NAV of equity
Fondbolaget Fondita Ab 20.1% EV/EBIT, P/AuM
HealthInvest Partners AB 45.8% Accrued acquisition value/NAV of equity
Teknik Innovation Norden Fonder AB 35.2% P/AuM
Holdings in Bure Growth AB 1 362
BioLamina AB 46.5% Latest transaction
My Driving Academy Sweden AB 30.4% Latest transaction, DCF
ScandiNova Systems AB 27.9% Latest transaction, EV/EBIT
Yubico AB 17.6% Latest transaction, EV/Sales

Note 5 – Classification of financial instruments

Group
31 December 2023
SEK M
Financial assets and liabilities
valued at fair value from
income statements
Financial assets and
liabilities valued at accrued
acquisition cost
Total carrying
amount
Financial assets
Financial assets valued at fair value from the income statements 17,529 17,529
Other long-term receivables 45 45
Other short-term receivables 3 3
Short-term investments 122 122
Cash and bank balances 1,454 1,454
Total financial assets 17,652 1,502 19,153
Financial liabilities
Leasing liabilities 3 3
Other long-term liabilities 16 16
Other non-interest-bearing liabilities 36 36
Total financial liabilities 54 54
Group
31 December 2022
SEK M
Financial assets and liabilities
valued at fair value from
income statements
Financial assets and
liabilities valued at accrued
acquisition cost
Total carrying
amount
Financial assets
Financial assets valued at fair value from the income statements 14,027 14,027
Other long-term receivables 42 42
Other short-term receivables 4 4
Short-term investments 116 116
Cash and bank balances 416 416
Total financial assets 14,144 461 14,605
Financial liabilities
Leasing liabilities 3 3
Other long-term liabilities 52 52
Other non-interest-bearing liabilities 21 21
Total financial liabilities 76 76

Note 6 – Financial position

Net loan receivable: Cash and cash equivalents, interest-bearing investments and interest-bearing current and non-current receivables minus interest-bearing current and non-current liabilities.

Group, SEK M 31 December 2023 31 December 2022
Cash and cash equivalents 1,454 416
Current interest-bearing receivables 1 2
Non-current interest-bearing receivables 45 41
Interest-bearing assets 1,499 459
Current interest-bearing leasing liabilities 2 2
Non-current interest-bearing leasing liabilities 1 1
Interest-bearing liabilities 3 3
Net receivable at end of the year 1,496 456
Parent Company, SEK M 31,December,2023 31,December,2022
Cash and cash equivalents 1,448 408
Current interest-bearing receivables 147 83
Non-current interest-bearing receivables 35 33
Interest-bearing assets 1,630 523
Current interest-bearing leasing liabilities 2 2
Non-current interest-bearing leasing liabilities 1 1
Interest-bearing liabilities 3 3

Bure Equity finances operations in Atle Investment Management and Bure Growth with equity and loans. The table below presents internal loans in the Bure Group.

Internal receivables within the Group
SEK M 31 December 2023 31 December 2022
Atle Investment Management 147 81
Bure Growth 0 449
Total 147 531

Note 7 – Issued securities and contingent liabilities

As of 31 December 2023, the investment entity had not issued any security and had not entered into any contingent liabilities. No additional purchase costs that had not already been debited occurred within the investment entity.

Alternative Performance Measures and definitions

Bure's reporting includes key financial figures that are based on IFRS rules. The company also uses Alternative Performance Measures (APMs). Bure applies European Securities and Markets Authority's guidelines for APMs. APMs are used in certain contexts when they supplement measures defined in applicable financial reporting rules. APM definitions are described below.

Change in net asset value per share

Change in net asset value per share on the balance sheet date compared to net asset value at the beginning of the period.

Direct return

Dividend per share in relation to the market price per share on the balance sheet date.

Earnings per share

Profit after tax divided by the average number of shares outstanding during the period.

Earnings per share after dilution

Profit after tax divided by the period's average number of outstanding shares after dilution.

EBIT

Operating profit before interest and tax.

EBIT margin

Operating profit before interest and tax divided by net sales.

EBITDA

Operating profit before depreciation, interest and taxes.

EBITDA margin

Operating profit before depreciation, interest and taxes divided by net sales.

Equity per share

Equity divided by the number of outstanding shares.

Equity per share excluding repurchased shares

Equity divided by the number of outstanding shares excluding repurchased shares.

Equity ratio

Equity in relation to balance sheet total.

GHG Protocol definitions

Scope 1: Greenhouse gas emissions from sources directly controlled by the company.

Scope 2: Indirect greenhouse gas emissions caused by the use of electricity, heating and cooling.

Scope 3: All indirect emissions that are not included in Scope 2 that occur upstream and downstream in the value chain.

IRR

Internal rate of return.

Management costs/net asset value

Management costs during the period divided by net asset value at the end of the period.

Net debt

Also defined as net loan receivables, although this term is used when interest-bearing liabilities exceed interest-bearing assets.

Net asset value

Market value (valued at fair value) of Bure's listed and unlisted holdings and short-term investments and the value of other net assets and cash and cash equivalents.

Net loan receivables

Financial interest-bearing assets less interest-bearing liabilities.

Return on equity

Profit after tax divided by average equity on the balance sheet date and at the start of the period.

Share price as a percentage of net asset value

The share price on the balance sheet date divided by net asset value on the balance sheet date.

SIX Return Index

The SIX RX index is a Swedish yield index calculated on share price changes and reinvested dividends.

Stock market value

The share price multiplied by the total number of outstanding shares.

Total return

Sum of the period's price increase and reinvested dividend divided by the share price at the beginning of the period.

This is Bure

Bure is a listed investment company that is quoted on Nasdaq Stockholm Large Cap. The portfolio consisted of eleven companies, of which seven are listed holdings.

Our business concept is to be a long-term principal owner of operating companies. Through far-reaching engagement and value-driving initiatives and activities, we support the portfolio companies in becoming successful in their respective businesses.

Our objective is to create a long-term sustainable total return for our shareholders and to be a competitive investment alternative in the market.

Bure's strategic cornerstones are:

  • Long-term approach
  • Commitment and responsibility
  • Adapted leadership
  • Financial strength

Financial calendar

Interim report January–March 2024 13 May 2024 Interim report January–June 2024 16 August 2024 Interim report January–September 2024 8 November 2024

For information contact

Henrik Blomquist, CEO: +46 8 614 00 20 Max Jonson, CFO: +46 8 614 00 20